RAD001 and ZOledronic acid in Renal cell carcinoma patients with bone metastases (RAZOR) ??? a randomised phase II trial
Author: Hinder, Victoria; Broom, RJ; Pollard, S; Sharples, K; Fong, P; Hanning, F; Deva, S; Forgeson, G; Jameson, Michael; O'Donnell, A; Harris, D; North, R; Grey, A; Findlay, Michael
Publisher: The Authors
Type: Conference item
Link to this item using this URL: http://hdl.handle.net/2292/18917
Bone metatases from renal cell carcinoma are common, destructive and have been identified as an adverse prognostic feature, even in the modern targeted therapy era.
Citation: ["New Zealand Society of Oncology, Auckland, 12 May 2011 - 13 May 2011."]